Athira Pharma’s experimental Alzheimer’s drug, fosgonimeton, failed to demonstrate a statistically significant improvement in cognition and function in a Phase 2/3 clinical trial. While the drug showed promising trends in certain patient subgroups, the overall results fell short of expectations, leading to a substantial drop in the company’s stock price.